According to a new report published by Introspective Market Research, titled, Myomectomy Market by Procedure Type, End-User, and Region, The Global Myomectomy Market Size Was Valued at USD 1.90 Billion in 2023 and is Projected to Reach USD 4.09 Billion by 2032, Growing at a CAGR of 8.89%. The Myomectomy Market is witnessing significant growth due to the increasing prevalence of uterine fibroids among women of reproductive age. Myomectomy, a surgical procedure to remove fibroids while preserving the uterus, is considered the gold standard for women who wish to maintain fertility. The demand for this procedure is growing steadily as awareness about uterine health increases and advancements in minimally invasive surgery enhance treatment outcomes.
Compared to hysterectomy, myomectomy offers a uterus-sparing alternative that is preferred by younger patients and those concerned about hormonal changes post-surgery. The adoption of robotic-assisted and laparoscopic techniques has significantly reduced recovery times, surgical risks, and hospital stays. With rising healthcare expenditures, supportive reimbursement policies, and technological innovation, the myomectomy market is poised for sustained expansion, especially in developed and emerging economies alike.
The Myomectomy Market is segmented into Procedure Type, End-User, and Region. By Procedure Type, the market is categorized into (Abdominal Myomectomy, Laparoscopic Myomectomy, Hysteroscopic Myomectomy). By End-User, the market is categorized into (Hospitals, Specialty Clinics, Ambulatory Surgical Centers). By Region, the market is categorized into (North America, Europe, Asia-Pacific, South America, Middle East & Africa).
One of the key growth drivers in the Myomectomy Market is the increasing incidence of uterine fibroids, particularly among women aged 30–50. Factors such as hormonal imbalances, obesity, and delayed pregnancies contribute to the rising prevalence. Additionally, the growing awareness of fertility-preserving surgical options has led more women to opt for myomectomy over hysterectomy. As gynecologists and patients lean towards less invasive procedures with quicker recovery, the demand for advanced myomectomy techniques continues to accelerate globally.
An important market opportunity lies in the adoption of robotic-assisted myomectomy procedures. These systems offer greater surgical precision, reduced blood loss, and minimal scarring, which translate to better patient outcomes. As robotic surgery becomes more accessible and cost-effective, especially in high-income and emerging economies, manufacturers and healthcare providers are increasingly investing in this segment. Additionally, ongoing innovations in energy devices and visualization tools present new avenues for market players to differentiate and expand their offerings.
Myomectomy Market, Segmentation
The Myomectomy Market is segmented on the basis of Procedure Type, End-User, and Region.
Procedure Type
The Procedure Type segment is further classified into Abdominal Myomectomy, Laparoscopic Myomectomy, and Hysteroscopic Myomectomy. Among these, the Laparoscopic Myomectomy sub-segment accounted for the highest market share in 2023. The preference for laparoscopic procedures stems from their minimally invasive nature, reduced post-operative pain, and shorter hospital stays. As hospitals continue to adopt advanced surgical systems and patient demand for quick recovery grows, laparoscopic myomectomy has gained significant traction in gynecological practices worldwide.
End-User
The End-User segment is further classified into Hospitals, Specialty Clinics, and Ambulatory Surgical Centers. Among these, the Hospitals sub-segment accounted for the highest market share in 2023. Hospitals offer comprehensive facilities, skilled surgeons, and post-operative care infrastructure, making them the primary setting for myomectomy procedures. Their ability to handle complex cases, coupled with favorable reimbursement policies and insurance coverage, continues to support this segment’s dominance across both developed and developing regions.
Some of The Leading/Active Market Players Are–
- Hologic Inc. (USA)
- Medtronic plc (Ireland)
- CooperSurgical Inc. (USA)
- Olympus Corporation (Japan)
- Karl Storz SE & Co. KG (Germany)
- Richard Wolf GmbH (Germany)
- Stryker Corporation (USA)
- Johnson & Johnson (Ethicon) (USA)
- Boston Scientific Corporation (USA)
- ConMed Corporation (USA)
- Intuitive Surgical, Inc. (USA)
- Zimmer Biomet Holdings, Inc. (USA)
- B. Braun Melsungen AG (Germany)
- and other active players.
Key Industry Developments
In March 2024, Medtronic launched a next-generation laparoscopic surgical platform designed specifically for gynecological procedures, including myomectomy. The system includes advanced 3D imaging, AI-assisted tissue recognition, and energy-efficient cutting tools. Its ergonomic design and automation features aim to enhance surgical efficiency and reduce intra-operative complications, boosting its appeal among hospitals and outpatient surgical centers.
In July 2024, Hologic Inc. announced a strategic collaboration with a digital health company to develop a post-myomectomy remote monitoring platform. This platform integrates wearable biosensors and mobile applications to track patient recovery metrics such as mobility, pain levels, and wound healing. The initiative aims to reduce hospital readmissions, optimize patient outcomes, and create a value-based care model for gynecological surgeries.
Key Findings of the Study
- Laparoscopic myomectomy dominates due to patient preference for minimally invasive surgery.
- Hospitals lead the market due to infrastructure, surgeon availability, and insurance coverage.
- Rising uterine fibroid incidence globally fuels demand for surgical solutions.
- Robotic and AI-driven systems present promising growth opportunities in surgical gynecology.
